Australia markets close in 4 hours 5 minutes

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1849-0.0117 (-5.95%)
At close: 04:00PM EDT
0.1801 -0.00 (-2.60%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1966
Open0.1942
Bid0.1750 x 1000
Ask0.1800 x 1100
Day's range0.1750 - 0.1950
52-week range0.1300 - 1.1300
Volume879,078
Avg. volume1,351,521
Market cap22.204M
Beta (5Y monthly)0.42
PE ratio (TTM)N/A
EPS (TTM)-0.3470
Earnings date26 July 2022 - 01 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • GlobeNewswire

    Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS

    Patients demonstrated statistically significant improvements in several hormonal and cardiometabolic parameters following treatment with DCCRREDWOOD CITY, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today presented new positive clinical data from its ongoing late-stage DCCR development program for the treatment of Prader-Will

  • GlobeNewswire

    Soleno Therapeutics Announces Presentations at ENDO 2022

    REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (β€œSoleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA. Details of the presentations are as follows: 2022 Endocrine Society Meeting (ENDO) Title:Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline E

  • GlobeNewswire

    Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology

    REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (β€œSoleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy. Details of the presentations are as follows: 2022 European Congress of Endocrinology (ECE) Title:DCCR UpdateFormat:Presentation at the I